R M Goldberg

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program
    Richard M Goldberg
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:4591-6. 2002
  2. ncbi request reprint Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer
    R M Goldberg
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:3320-9. 1997
  3. ncbi request reprint Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group
    R M Goldberg
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 129:27-35. 1998
  4. ncbi request reprint Oxaliplatin in colorectal cancer: current studies
    R Goldberg
    Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 14:42-7. 2000
  5. ncbi request reprint Adjuvant chemotherapy for colon cancer
    S K Kumar
    Division of Medical Oncology, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 3:94-101. 2001
  6. ncbi request reprint Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
    S R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 14:580-5. 2003
  7. ncbi request reprint A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 89:1699-705. 2000
  8. ncbi request reprint Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
    S R Alberts
    Division of Medical Oncology and Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 12:627-31. 2001
  9. ncbi request reprint Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:2910-9. 1997
  10. ncbi request reprint Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Clin Oncol 18:1116-23. 2000

Collaborators

Detail Information

Publications83

  1. ncbi request reprint Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program
    Richard M Goldberg
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:4591-6. 2002
    ..We believe the methods described present opportunities for improving patient safety in clinical research...
  2. ncbi request reprint Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer
    R M Goldberg
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:3320-9. 1997
    ..V.) (d,l)-leucovorin...
  3. ncbi request reprint Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group
    R M Goldberg
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 129:27-35. 1998
    ..Follow-up testing after surgery for colon cancer is recommended principally to identify resectable recurrences, but data on the efficacy of, outcomes of, and optimal strategies for this testing are limited...
  4. ncbi request reprint Oxaliplatin in colorectal cancer: current studies
    R Goldberg
    Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 14:42-7. 2000
    ....
  5. ncbi request reprint Adjuvant chemotherapy for colon cancer
    S K Kumar
    Division of Medical Oncology, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 3:94-101. 2001
    ..In this article, we discuss the evolution and the current state of adjuvant chemotherapy in colon cancer and briefly review new developments...
  6. ncbi request reprint Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
    S R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 14:580-5. 2003
    ..This study was performed to determine the efficacy of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA)...
  7. ncbi request reprint A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 89:1699-705. 2000
    ....
  8. ncbi request reprint Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
    S R Alberts
    Division of Medical Oncology and Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 12:627-31. 2001
    ..CONCLUSIONS: The maximum tolerated dose for this study recommended for phase II testing is gemcitabine 1000 mg/m2 and CPT-11 100 mg/m2. A partial response was seen in transitional cell carcinoma...
  9. ncbi request reprint Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    H C Pitot
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:2910-9. 1997
    ..To evaluate the objective tumor response rate and toxicities of patients with metastatic colorectal carcinoma treated with irinotecan hydrochloride (CPT-11)...
  10. ncbi request reprint Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Clin Oncol 18:1116-23. 2000
    ....
  11. ncbi request reprint Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 18:1748-57. 2000
    ..Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors. A phase I trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy...
  12. ncbi request reprint Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741
    T Delaunoit
    Department of Oncology, Cancer Center Statistics, Mayo Clinic, 200 First St Southwest, Rochester, MN 55905, USA
    Ann Oncol 16:425-9. 2005
    ..Here we identify and describe patients treated on Intergroup study N9741 who initially had inoperable MCRC, but who obtained sufficient chemotherapeutic benefit to allow removal of their metastatic disease...
  13. ncbi request reprint A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients
    D J Sargent
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 345:1091-7. 2001
    ..CONCLUSIONS: Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects...
  14. ncbi request reprint Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
    C Erlichman
    Mayo Clinic Cancer Center, Rochester, Minnesota, USA
    Ann Oncol 12:389-95. 2001
    ..We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity...
  15. ncbi request reprint A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
    R M Goldberg
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 13:1674-80. 2002
    ....
  16. ncbi request reprint Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic
    H J Long
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905
    Invest New Drugs 9:349-51. 1991
    ....
  17. ncbi request reprint Future directions in adjuvant therapy for stage III colon carcinoma
    H C Pitot
    Division of Medical Oncology, Mayo Cancer Center, Gastrointestinal Cancer Research Program, Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 15:31-6. 2001
    ..Future and ongoing investigations will look to integrate these new therapies as we attempt to move beyond the era of 5-FU and leucovorin...
  18. ncbi request reprint Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study
    S R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 13:553-7. 2002
    ..The study was performed to determine the maximum tolerated dose (MTD) of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA)...
  19. pmc Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
    D Sargent
    NCCTG, Mayo Clinic, Rochester, MN, USA
    Eur J Cancer 47:990-6. 2011
    ..The relationship between end-points in trials with oral fluoropyrimidines, oxaliplatin and irinotecan is unknown...
  20. ncbi request reprint Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd)
    E Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 12:701-7. 2001
    ..Evidence of potential antitumor activity was observed: 1 patient (with colon cancer) had a partial response while 15 others had stable disease...
  21. ncbi request reprint A three-outcome design for phase II clinical trials
    D J Sargent
    Section of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Control Clin Trials 22:117-25. 2001
    ..We describe the theoretical properties of this design and illustrate it with several examples. We focus on the clinical implications of the three-outcome design. Control Clin Trials 2001;22:117-125..
  22. ncbi request reprint A flexible design for multiple armed screening trials
    D J Sargent
    Section of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Stat Med 20:1051-60. 2001
    ..The goal of this design is to mirror clinical practice, where a treatment's success probability is often only one of many considerations in determining a treatment recommendation for a particular patient...
  23. ncbi request reprint Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction
    Larry J Schaaf
    Clinical Treatment Unit, The Ohio State University Comprehensive Cancer Center, 1248 James Cancer Hospital, 300 West 10th Avenue, Columbus, 43210, USA
    Clin Cancer Res 12:3782-91. 2006
    ..To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule...
  24. ncbi request reprint Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
    Richard M Goldberg
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:4085-91. 2006
    ..This analysis compares the safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients age younger than and at least 70 years...
  25. ncbi request reprint Thymidylate synthase expression in colon carcinomas with microsatellite instability
    Frank A Sinicrope
    Mayo Clinic and Mayo College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:2738-44. 2006
    ..Given that thymidylate synthase (TS) is inhibited by 5-FU, we studied the relationship between MSI and TS expression, and the prognostic effect of these and other markers (i.e., p53 and 17p allelic imbalance)...
  26. ncbi request reprint Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901
    David P Ryan
    Massachusetts General Hospital Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2557-62. 2006
    ..This phase I/II study evaluated the addition of weekly oxaliplatin to preoperative continuous infusion fluorouracil (FU) and external-beam radiation therapy (RT) in patients with locally advanced rectal adenocarcinoma...
  27. ncbi request reprint Intensive surveillance after stage II or III colorectal cancer: is it worth it?
    Richard M Goldberg
    J Clin Oncol 24:330-1. 2006
  28. ncbi request reprint Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
    Richard M Goldberg
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27514, USA
    J Clin Oncol 24:3347-53. 2006
    ..High rates of grade > or = 3 toxicity on IFL (resulting in some deaths) led us to reduce the starting doses of both irinotecan and FU by 20% (rIFL). This article compares rIFL with FOLFOX4...
  29. ncbi request reprint Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials
    Michelle R Mahoney
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 23:9275-81. 2005
    ..We assessed the utility of the RAE data collected, relative to the volume...
  30. ncbi request reprint Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, Department of Clinical Medicine, University of California San Francisco, 600 Divisadero Box 1770, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 5:292-4. 2005
  31. ncbi request reprint Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
    Daniel J Sargent
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:8664-70. 2005
    ..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
  32. ncbi request reprint Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 23:9243-9. 2005
    ..The use of neoadjuvant chemotherapy to improve the likelihood of resection in disease that is not optimally resectable has not been as well studied...
  33. ncbi request reprint Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma
    Bruce E Hillner
    Department of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Cancer 104:1871-84. 2005
    ..The trade-offs between costs and survival for these two regimens have not been explored...
  34. ncbi request reprint Cetuximab in the treatment of colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina, Chapell Hill, NC, USA
    Clin Adv Hematol Oncol 2:1-10; quiz 11-12. 2004
  35. ncbi request reprint Systemic therapy for metastatic colorectal cancer: current options, current evidence
    Hanna Kelly
    Division of Hematology and Oncology, University of North Carolina, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 23:4553-60. 2005
    ..Sound clinical judgment must continue to guide treatment decisions while we await data regarding the optimal combination and sequence of fluorouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab...
  36. ncbi request reprint Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients
    Frank A Sinicrope
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 131:729-37. 2006
    ..Given that high-frequency MSI (MSI-H) and diploidy are correlated, we determined whether they are independent prognostic variables...
  37. ncbi request reprint The role of targeted therapy in the treatment of colorectal cancer
    Richard M Goldberg
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Additional targeted agents are also being developed and are showing promise in clinical trials...
  38. pmc Association of family history with cancer recurrence and survival among patients with stage III colon cancer
    Jennifer A Chan
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:2515-23. 2008
    ..However, the influence of family history on cancer recurrence and survival among patients with established disease remains uncertain...
  39. doi request reprint Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281)
    Neal J Meropol
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3229-34. 2008
    ....
  40. doi request reprint Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 26:2336-41. 2008
    ....
  41. pmc Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:521-6. 2008
    ..This trial was designed to determine the maximum tolerated dose and dose limiting toxicities (DLT) of nab-paclitaxel in combination with gemcitabine...
  42. doi request reprint Chemotherapy in elderly patients with colorectal cancer
    Claus Henning Köhne
    Klinik für Onkologie Hämatologie, Klinikum Oldenburg, Dr Eden Str 10, 26133 Oldenburg, Germany
    Oncologist 13:390-402. 2008
    ..The management of frail elderly patients and those with a short life expectancy should be focused on palliation, while fit elderly patients can receive aggressive therapy in a similar fashion to younger patients...
  43. ncbi request reprint A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903
    Mitchell C Posner
    University of Chicago, 5841 S Maryland Avenue MC5031, Chicago 60637, IL, USA
    Ann Surg Oncol 15:158-64. 2008
    ....
  44. ncbi request reprint End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group
    Daniel J Sargent
    Department of Health Sciences Research, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:4569-74. 2007
    ..We previously validated disease-free survival (DFS) after 3-year follow-up as an excellent predictor of 5-year OS results. Here we explore shorter term DFS and OS end points, as well as stage dependency...
  45. ncbi request reprint Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
    ..To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach...
  46. ncbi request reprint Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:3456-61. 2007
    ..We evaluated the efficacy and safety of weekly bolus CPT-11 plus FU plus LV in the treatment of patients with completely resected stage III colon cancer...
  47. ncbi request reprint Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:670-7. 2007
    ..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741...
  48. ncbi request reprint Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, University of California, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 6:536-8. 2007
  49. pmc Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  50. ncbi request reprint The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....
  51. ncbi request reprint Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability
    Frank A Sinicrope
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Int J Cancer 120:1232-8. 2007
    ....
  52. ncbi request reprint Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow
    Anne W Beaven
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, USA
    Oncology (Williston Park) 20:461-9; discussion 469-70, 473-5. 2006
    ..Finally, a look to the future shows monoclonal antibodies to be an avenue of great promise infighting colorectal cancer...
  53. ncbi request reprint Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1402-10. 2005
    ..The insulin-like growth factor (IGF) family of proteins is associated with QOL in noncancer populations. We sought to study whether these proteins are associated with QOL in patients with colorectal cancer...
  54. ncbi request reprint New targeted therapies in gastrointestinal cancers
    Sharlene Gill
    Division of Hematology Oncology, The University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA
    Curr Treat Options Oncol 4:393-403. 2003
    ..The results of ongoing and future research efforts will clarify the optimal use and survival benefit of targeted therapies for patients with GI malignancies...
  55. pmc Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
    Christine M Ribic
    Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Toronto
    N Engl J Med 349:247-57. 2003
    ..We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer...
  56. ncbi request reprint A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003
    ..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
  57. ncbi request reprint Optimal use of the combination of irinotecan and 5-fluorouracil
    Al B Benson
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, USA
    Semin Oncol 30:68-77. 2003
    ..Future directions include the testing of a complex array of new agents and the incorporation of laboratory predictors of survival and response as a component of clinical trial design...
  58. ncbi request reprint CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Gastrointest Cancer 32:107-14. 2002
    ..These cancers are typically refractory to standard chemotherapy agents. Based on preclinical work showing activity of CPT-11, we performed a phase II trial to assess its activity in patients with bile-duct or gallbladder carcinomas...
  59. ncbi request reprint A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer
    James A Martenson
    Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 55:1305-10. 2003
    ..Gemcitabine's radiosensitizing properties can theoretically be exploited by twice-weekly administration. This study assessed toxicity in patients with pancreatic cancer treated with radiation therapy, gemcitabine, and cisplatin...
  60. ncbi request reprint Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer
    Timothy J Hobday
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 2:161-9. 2002
    ..Herein, we review recent developments in combination and sequential chemotherapy for metastatic colorectal cancer and the implications for the optimal treatment in these patients...
  61. ncbi request reprint Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma
    Timothy J Hobday
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4574-80. 2002
    ..To evaluate quality of life (QOL) and tumor response after administration of an oral chemotherapy regimen in patients with previously untreated metastatic colorectal cancer...
  62. ncbi request reprint N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer
    Richard M Goldberg
    Mayo Clinic, Rochester, MN, USA
    Clin Colorectal Cancer 2:81. 2002
  63. ncbi request reprint A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Mayo Graduate School, Rochester, MN 55905, USA
    Invest New Drugs 20:297-304. 2002
    ..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...
  64. ncbi request reprint Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer
    Carmen J Allegra
    National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 20:1735-43. 2002
    ..To evaluate the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with Dukes' B2 and C colon carcinoma...
  65. ncbi request reprint Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:1491-8. 2002
    ..After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken...
  66. ncbi request reprint A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:712-7. 2002
    ..To evaluate the toxicities, characterize the pharmacokinetics, and determine the maximum-tolerated dose of bizelesin administered once every 4 weeks...
  67. ncbi request reprint Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
    Matthew P Goetz
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:3761-9. 2003
    ..Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics...
  68. ncbi request reprint A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
    ..In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease...
  69. ncbi request reprint First-line treatment strategies to improve survival in patients with advanced colorectal cancer
    Sharlene Gill
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Drugs 64:27-44. 2004
    ..Further improvements in the management of advanced disease will continue to be pursued through the ongoing development of multimodality approaches and the incorporation of novel targeted agents with innovative chemotherapy combinations...
  70. ncbi request reprint Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer
    Elizabeth A Poplin
    Operations Office, 14980 Omicron Dr, San Antonio, TX 78245 3217, USA
    J Clin Oncol 23:1819-25. 2005
    ....
  71. ncbi request reprint A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
    ..The present study was undertaken to evaluate the efficacy, toxicity, and pharmacokinetics of gemcitabine and pemetrexed when pemetrexed is administered immediately after gemcitabine...
  72. ncbi request reprint Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can)
    BERT H O'NEIL
    UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 32:35-42. 2005
    ..Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article...
  73. ncbi request reprint 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study
    Stacy D'Andre
    University of California, Davis, Sacramento, CA, USA
    Clin Colorectal Cancer 4:325-31. 2005
    ..Age alone should not be used to determine whether older patients are treated, because performance status is predictive of dose intensity, response rate, time to tumor progression, and overall survival...
  74. ncbi request reprint Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer
    Shannon K Penland
    The University of North Carolina at Chapel Hill, NC 27599 7305, USA
    Clin Colorectal Cancer 4:S74-80. 2004
    ..Specifically, studies evaluating VEGF-targeted agents in combination with oxaliplatin-containing regimens in CRC are discussed...
  75. ncbi request reprint Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741
    Thierry Delaunoit
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:2170-6. 2004
    ..The complications observed in these arms highlight the importance of aggressive and immediate supportive care in the management of digestive toxicity...
  76. ncbi request reprint A review of oxaliplatin and its clinical use in colorectal cancer
    Axel Grothey
    Mayo Clinic, Rochester, MN, USA
    Expert Opin Pharmacother 5:2159-70. 2004
    ....
  77. ncbi request reprint Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, The University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    Cancer Chemother Pharmacol 54:S57-64. 2004
    ..In this paper selected phase III studies from around the globe that tested these new chemotherapy options and led to new standards of care and better expectations for patients with advanced colorectal cancer are reviewed...
  78. ncbi request reprint Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130
    James A Martenson
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 22:3277-83. 2004
    ..Some patients with colon cancer have a high risk of local recurrence postoperatively. This trial was undertaken to determine whether radiation therapy added to an adjuvant chemotherapy regimen improves outcome in high-risk patients...
  79. ncbi request reprint Current strategies in previously untreated advanced colorectal cancer
    Shannon K Penland
    Division of Hematology Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Oncology (Williston Park) 18:715-22, 727; discussion 727-9. 2004
    ..Survival in patients with advanced colorectal cancer is on a positive trajectory. The hope that some patients with advanced disease will be long-term survivors (even without surgery) appears to be within the range of possibility...
  80. ncbi request reprint Current approaches to first-line treatment of advanced colorectal cancer
    Richard M Goldberg
    Division of Hematolgy Oncology, University of North Carolina at Chapel Hill, 27599 7305, USA
    Clin Colorectal Cancer 4:S9-15. 2004
    ..The history and development of 5-FU-based treatment regimens that include the newer drugs irinotecan, oxaliplatin, and bevacizumab are discussed in light of the impact these advances have made in the treatment of colorectal cancer..
  81. ncbi request reprint Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Sharlene Gill
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:1797-806. 2004
    ....
  82. ncbi request reprint Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:1209-14. 2004
    ..However, the importance of the availability of all three active cytotoxic agents, FU-LV, irinotecan, and oxaliplatin, on overall survival (OS) has not yet been evaluated...
  83. ncbi request reprint Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors
    Noralane M Lindor
    Department of Medical Genetics, Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:1043-8. 2002
    ..To compare microsatellite instability (MSI) testing with immunohistochemical (IHC) detection of hMLH1 and hMSH2 in colorectal cancer...